Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.94 USD | -0.13% | -12.07% | -22.99% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.99% | 228M | |
+11.31% | 226B | |
+15.50% | 198B | |
+18.83% | 142B | |
+30.38% | 111B | |
+2.62% | 65.26B | |
+18.31% | 54.36B | |
+4.96% | 50.94B | |
+9.95% | 44.8B | |
+4.27% | 36.8B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Earnings Flash (NPCE) NEUROPACE Posts Q1 Revenue $18.1M, vs. Street Est of $17.3M